Literature DB >> 21287281

The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?

Sanjay P Bagaria1, Jaime Shamonki, Michelle Kinnaird, Partha S Ray, Armando E Giuliano.   

Abstract

BACKGROUND: Lobular carcinoma in situ (LCIS) is considered a risk factor-not a precursor-for both invasive lobular and ductal carcinoma. Florid LCIS (F-LCIS) is an architectural subtype of LCIS that does not express E-cadherin, yet has the histologic and often radiographic appearance of solid-type ductal carcinoma in situ (DCIS). Since DCIS is considered a precursor to invasive ductal carcinoma, should F-LCIS be considered a precursor to invasive lobular carcinoma (ILC)?
METHODS: Review of an institutional database identified cases of LCIS and solid-type DCIS diagnosed by excisional biopsy, segmentectomy, or mastectomy between 1991 and 2000 to determine the prevalence of associated invasive breast cancer. Archival specimens were evaluated for florid and nonflorid LCIS, nuclear grade of LCIS, and the presence and subtype of invasive breast cancer. Solid-type DCIS that lacked E-cadherin expression was classified as F-LCIS.
RESULTS: Of 210 consecutive specimens of LCIS examined, 171 had nonflorid LCIS (81%) and 39 had F-LCIS (19%). Nonflorid LCIS had a diffuse pattern, whereas F-LCIS appeared as discrete foci adjacent to ILC. An invasive component was identified with 87% of F-LCIS lesions versus 73% of nonflorid LCIS lesions (P = 0.064); this component was lobular in 100% of F-LCIS lesions versus 82% of nonflorid LCIS lesions, a significant difference (P = 0.0044) that persisted when the analysis was adjusted for nuclear grade (P = 0.0082).
CONCLUSION: Its close spatial relationship to an invasive component and increased association with ILC suggest that F-LCIS may be a precursor for ILC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287281     DOI: 10.1245/s10434-011-1563-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications.

Authors:  Stuart J Schnitt; Edi Brogi; Yunn-Yi Chen; Tari A King; Sunil R Lakhani
Journal:  Ann Diagn Pathol       Date:  2020-02-15       Impact factor: 2.090

Review 2.  [Lobular neoplasms and invasive lobular breast cancer].

Authors:  H-P Sinn; B Helmchen; J Heil; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

3.  Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.

Authors:  Eliah R Shamir; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2020-01-06       Impact factor: 7.842

4.  Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases.

Authors:  Thaer Khoury; Rouzan G Karabakhtsian; David Mattson; Li Yan; Susanna Syriac; Fadi Habib; Song Liu; Mohamed M Desouki
Journal:  Histopathology       Date:  2014-02-25       Impact factor: 5.087

Review 5.  Molecular drivers of lobular carcinoma in situ.

Authors:  Greg J Logan; David J Dabbs; Peter C Lucas; Rachel C Jankowitz; Daniel D Brown; Beth Z Clark; Steffi Oesterreich; Priscilla F McAuliffe
Journal:  Breast Cancer Res       Date:  2015-06-04       Impact factor: 6.466

6.  Pleomorphic lobular carcinoma in situ: Current evidence and a systemic review.

Authors:  Umar Wazir; Ali Wazir; Clive Wells; Kefah Mokbel
Journal:  Oncol Lett       Date:  2016-11-01       Impact factor: 2.967

7.  Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study.

Authors:  Pu Cheng; Qi Huang; Jiafeng Shou; Guoming Hu; Mengjiao Han; Jian Huang
Journal:  Oncotarget       Date:  2017-10-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.